Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on the risk of venous thromboembolism in patients with obesity: a real-world cohort study - PubMed
4 hours ago
- #Obesity
- #Tirzepatide
- #Venous Thromboembolism
- Tirzepatide showed a significantly lower 1-year risk of venous thromboembolism (VTE) compared to GLP-1 receptor agonists in patients with obesity (HR 0.90, 95% CI 0.83-0.98).
- The reduction in VTE risk was primarily driven by lower incidence of pulmonary embolism (PE; HR 0.88, 95% CI 0.79-0.98) and all-cause mortality (HR 0.90, 95% CI 0.82-0.99), with no significant difference in deep vein thrombosis (DVT).
- The study used a large real-world cohort of 701,374 matched patients from the TriNetX database, employing propensity score matching and an active-comparator, new-user design to control for confounders.
- Findings are observational and hypothesis-generating, not establishing causality, with residual confounding assessed via negative control outcomes and E-values.
- The research addresses a gap in evidence regarding tirzepatide's effects on VTE risk, highlighting its potential additional benefit over GLP-1 RAs in obesity management.